Search Results for "EyleaHD"

Phase 2/3 Clinical Trial Data for EYLEA HD® (aflibercept) Injection 8 mg for the Treatment of DME

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Phase 3 Clinical Trial Data for EYLEA HD® (aflibercept) Injection 8 mg for the Treatment of Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Switching Agents in DME

Michael Javaheri, MD

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

Ben Young, MD; Pheobe Mellen, MD; and Jordan Deaner, MD

A Treatment Paradigm for Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE

Philip Storey, MD; and Prof. Sobha Sivaprasad

New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

View More